GlassScriptPhysician profile
Suresh Kumar Misra
NPI 1013228964
$3,002.43
in general payments reported to CMS, 2019-2025
27 companies · $578 in 2025
The $578 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.15 · 2020: $11.26 · 2021: $46.75 · 2022: $427 · 2023: $906 · 2024: $965 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,449.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $896.45 | 2022-2025 | |
| Janssen Biotech, INC. | $261.81 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $193.65 | 2022-2025 | |
| Boston Scientific Corporation | $189.02 | 2019-2023 | Captivator II |
| Takeda Pharmaceuticals U.S.A., INC. | $175.99 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $150.49 | 2023-2024 | Zeposia |
| Madrigal Pharmaceuticals | $149.54 | 2024-2025 | Resmetirom, Rezdiffra |
| Qol Medical, LLC | $145.38 | 2024-2025 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $123.14 | 2021-2024 | Injectafer |
| Mallinckrodt Hospital Products INC. | $97.43 | 2025 | Terlivaz |
| Glaxosmithkline, LLC. | $82.06 | 2019-2025 | Shingrix, Arexvy |
| Braintree Laboratories, INC. | $72.35 | 2022-2024 | Sutab, Suflave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.76 | 2022-2023 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $68.63 | 2022-2023 | Ocaliva |
| Ardelyx, INC. | $58.74 | 2023 | Ibsrela |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $52.97 | 2023 | Avsola, Amjevita |
| Aimmune Therapeutics, INC. | $32.82 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $30.15 | 2025 | Iqirvo |
| Sumitomo Pharma America, INC. | $24.77 | 2024 | Gemtesa |
| Ironwood Pharmaceuticals, INC | $19.48 | 2022 | |
| Ferring Pharmaceuticals INC. | $17.69 | 2024 | Rebyota |
| Stryker Corporation | $17.63 | 2025 | Neptune |
| Gilead Sciences, INC. | $16.36 | 2023 | |
| Merck Sharp & Dohme LLC | $15.54 | 2023 | Dificid |
| Lilly USA, LLC | $14.74 | 2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $13.58 | 2024 | Voquezna |
| Hologic Sales and Service, LLC | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Misra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.